Upgrade to FINVIZ Elite to get real-time quotes, intraday charts, and advanced charting tools. Subscribe to Elite

ATAI

AtaiBeckley Inc

Jan 05 • 09:30AM ET

3.82

-0.05 -1.29 %

Healthcare • Biotechnology • USA • NASD

Peers: CMPS MNMD GHRS HELP RLMD SLS ANIX RGLS VNDA

| Held by: ARKG IBB PSIL AVSC NUSC GWX ONEQ BBSC ISCG FHLC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	20.07%	Shs Outstand	363.21M	Perf Week	-6.14%
Market Cap	1.39B	Forward P/E	-	EPS next Y	-0.46	Insider Trans	13.51%	Shs Float	290.31M	Perf Month	-5.91%
Enterprise Value	1.28B	PEG	-	EPS next Q	-0.11	Inst Own	11.05%	Short Float	5.09%	Perf Quarter	-26.96%
Income	-	P/S	-	EPS this Y	31.20%	Inst Trans	5.06%	Short Ratio	2.93	Perf Half Y	38.91%
Sales	-	P/B	5.75	EPS next Y	28.71%	ROA	-	Short Interest	14.78M	Perf YTD	-6.60%
Book/sh	0.66	P/C	12.11	EPS next 5Y	20.38%	ROE	-	52W High	6.75 -43.41%	Perf Year	187.22%
Cash/sh	0.32	P/FCF	-	EPS past 3/5Y	3.72% 18.62%	ROIC	-	52W Low	1.15 232.17%	Perf 3Y	60.50%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-75.27% -	Gross Margin	-	Volatility	5.33% 6.13%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-89.51%	Oper. Margin	-	ATR (14)	0.25	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	7.90	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	39.58	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	7.90	EPS Q/Q	21.44%	SMA20	-8.12%	Beta	1.62	Target Price	12.40
Payout	-	Debt/Eq	0.02	Sales Q/Q	174.36%	SMA50	-13.09%	Rel Volume	1.06	Prev Close	3.87
Employees	54	LT Debt/Eq	0.02	Earnings	Nov 12 BMO	SMA200	10.32%	Avg Volume	5.04M	Price	3.82
IPO	Jun 18, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	-142.63% 949.02%	Trades		Volume	267,264	Change	-1.29%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-13-25	Initiated	Needham	Buy	$12
Jul-29-25	Initiated	Oppenheimer	Outperform	$14
Nov-18-24	Reiterated	H.C. Wainwright	Buy	$15 → $10
Apr-03-24	Upgrade	Maxim Group	Hold → Buy	$6
Nov-01-22	Initiated	Loop Capital	Buy	$18
Nov-30-21	Initiated	Maxim Group	Buy	$25
Nov-11-21	Initiated	ROTH Capital	Buy	$32
Oct-18-21	Initiated	H.C. Wainwright	Buy	$40
Sep-01-21	Initiated	Jefferies	Buy	$27
Jul-13-21	Initiated	RBC Capital Mkts	Sector Perform	$19
Jul-13-21	Initiated	Credit Suisse	Outperform	$25
Jul-13-21	Initiated	Cowen	Outperform
Jul-13-21	Initiated	Citigroup	Buy	$26
Jul-13-21	Initiated	Cantor Fitzgerald	Buy	$45
Jul-13-21	Initiated	Canaccord Genuity	Buy	$28
Jul-13-21	Initiated	Berenberg	Buy	$35
Jul-08-21	Initiated	Aegis Capital	Buy	$26

Show Previous Ratings

Jan-04-26 04:51PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-30-25 06:55PM	AtaiBeckley Completes Redomiciliation to the United States (GlobeNewswire)
Dec-27-25 07:43AM	JonesTrading Highlights Differentiated Pipeline at Atai Beckley N.V. (ATAI) (Insider Monkey)
Dec-25-25 08:30AM	The 1 Riskiest Investment That Paid Off in 2025 (Barchart)
Dec-23-25 09:33AM	Coty downgraded, Spruce Biosciences initiated: Wall Street's top analyst calls (The Fly)
07:00AM	Loading…
07:00AM	AtaiBeckley Added to the Nasdaq Biotechnology Index (NBI) (GlobeNewswire)
Dec-22-25 01:12PM	MarketBeat's Top 5 Rated Small-Cap Stocks (MarketBeat) +8.59%
Dec-18-25 01:14AM	Atai Life Sciences N.V. (ATAI) Secures Patent for Social Anxiety Disorder Formulation (Insider Monkey)
Dec-15-25 08:03AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Dec-11-25 07:00AM	AtaiBeckley Announces New U.S. Patent Granted for EMP-01, Strengthening Intellectual Property Portfolio (GlobeNewswire)
Nov-25-25 08:39AM	H.C. Wainwright Maintains Buy on Atai Beckley (ATAI) Following Breakthrough Therapy and Merger Completion (Insider Monkey)
Nov-19-25 07:32PM	Enhanced Fortifies Executive Leadership Team & Board of Directors (PR Newswire)
Nov-18-25 06:16AM	Atai Beckley N.V. (ATAI) Receives Buy Rating on BPL-003 Edge against Spravato (Insider Monkey)
Nov-13-25 09:00AM	AtaiBeckley to Participate in the Jefferies Global Healthcare Conference in London (GlobeNewswire)
Nov-12-25 07:00AM	AtaiBeckley Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights (GlobeNewswire)
07:00AM	Loading…
Nov-10-25 07:00AM	AtaiBeckley Announces Positive Topline Data from the Phase 2b Open-Label Extension Study of BPL-003, Supporting Safety and Efficacy of a Second Dose in Patients with Treatment-Resistant Depression (GlobeNewswire)
Nov-05-25 07:00AM	atai Life Sciences and Beckley Psytech Announce the Successful Completion of Their Strategic Combination to Create AtaiBeckley, a Global Leader in Transformative Mental Health Therapies (GlobeNewswire) -15.15%
Oct-20-25 05:29PM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire) -8.57%
12:00PM	atai Life Sciences (ATAI) Upgraded to Buy: Here's Why (Zacks)
Oct-17-25 08:06AM	Why Atai Life Sciences Stock Was So Lively This Week (Motley Fool) +17.70%
Oct-16-25 10:31PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) -8.05%
04:12PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
04:10PM	atai Life Sciences and Beckley Psytech Announce U.S. FDA Breakthrough Therapy Designation Granted to BPL-003, Underscoring its Potential in Treatment-Resistant Depression (GlobeNewswire)
Sep-24-25 07:09AM	atai and Beckleys psychedelic advances to pivotal TRD trial (Clinical Trials Arena)
Sep-23-25 07:21PM	Atai Life Sciences N.V. (ATAI) Advances Psychedelic Therapies for Mental Health, Drawing Investor Spotlight (Insider Monkey) +14.96%
05:51PM	Why Atai Life Sciences Stock Crushed It on Tuesday (Motley Fool)
02:50PM	Atai Life Sciences Experimental Depression Drug Shows Sustained Benefit In Treatment-Resistant Patients (Benzinga)
07:00AM	atai Life Sciences and Beckley Psytech Report Positive Phase 2a Data Demonstrating Improved Outcomes with a Two-Dose Induction Regimen of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire)
Sep-21-25 09:06PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Sep-20-25 02:43AM	H.C. Wainwright Affirms 'Buy' Rating on Atai Life Sciences N.V. (ATAI) on Psychedelic Prospects (Insider Monkey)
09:40AM	Loading…
Sep-19-25 09:40AM	Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? (Zacks)
08:10AM	Atai Life Sciences awarded grant worth up to $11.4M from NIH (TipRanks)
Sep-18-25 08:00AM	atai Life Sciences Awarded Grant from the National Institutes of Health (GlobeNewswire)
Sep-11-25 12:00PM	atai Life Sciences (ATAI) Upgraded to Buy: Here's What You Should Know (Zacks)
Sep-03-25 09:40AM	Are Medical Stocks Lagging Halozyme Therapeutics (HALO) This Year? (Zacks)
Sep-02-25 03:49AM	Atai Life Sciences N.V. (ATAI)'s BPL-003 Achieves Robust Phase 2b Success in Treatment-Resistant Depression (Insider Monkey)
Aug-28-25 04:05PM	atai Life Sciences to Participate in September Investor Conferences (GlobeNewswire)
Aug-25-25 11:56PM	H.C. Wainwright Reiterates a Buy Rating on Atai Life Sciences (ATAI) (Insider Monkey)
10:30AM	BC-Most Active Stocks (Associated Press Finance)
Aug-20-25 12:21AM	ATAI Life Sciences (ATAI) Rated as 'Outperform' at Oppenheimer on Psychedelic Prospects (Insider Monkey)
Aug-18-25 06:07PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
09:55AM	Here's Why atai Life Sciences (ATAI) Is a Great 'Buy the Bottom' Stock Now (Zacks)
Aug-14-25 07:00AM	atai Life Sciences Reports Second Quarter 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
Aug-04-25 10:01AM	Maxim Group Reiterates a Buy Rating on Atai Life Sciences (ATAI) With a $10 PT (Insider Monkey)
Jul-31-25 11:40PM	H.C. Wainwright Lifts PT on Atai Life Sciences (ATAI) to $15 From $10 (Insider Monkey) +18.16%
Jul-28-25 08:55AM	ATAI Life Sciences (ATAI) Stock Plunge on Trial Failure News (GuruFocus.com) -6.72%
06:17AM	Atai backs away from schizophrenia drug after trial failure (BioPharma Dive)
05:51AM	Recognifys Phase IIb trial of schizophrenia therapy fails to meet primary goal (Clinical Trials Arena)
Jul-25-25 04:05PM	Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia (GlobeNewswire)
Jul-21-25 12:00PM	atai Life Sciences (ATAI) Upgraded to Strong Buy: Here's Why (Zacks) +9.29%
Jul-11-25 07:13PM	Aegis Capital Reaffirms Buy on Atai Life Sciences N.V. (ATAI) with $8 Target (Insider Monkey)
09:40AM	Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jul-09-25 10:36AM	Canaccord Genuity Lifts Atai Life Sciences N.V. (ATAI)'s Price Target To $12, Maintains Buy Rating (Insider Monkey)
07:19AM	Atai Life Sciences, Beckley Psytech Announce Positive Topline Results for BPL-003 (Insider Monkey)
Jul-06-25 05:30AM	The MAHA Movement Loves Psychedelics. Should Wall Street? (The Wall Street Journal)
Jul-01-25 03:06PM	A Promising Depression Drug Works. Psychedelics Are Back. (Barrons.com) +23.74%
12:04PM	atai and Beckley Psytechs psychedelic wins in Phase IIb depression trial (Clinical Trials Arena)
07:15AM	Atai and Beckley, set to merge, reveal study success for psychedelic drug (BioPharma Dive)
06:05AM	atai Life Sciences Announces $50 Million Private Placement Financing (GlobeNewswire)
06:00AM	atai Life Sciences and Beckley Psytech Announce Positive Topline Results from the Phase 2b Study of BPL-003 in Patients with Treatment-Resistant Depression (GlobeNewswire)
Jun-25-25 09:40AM	Are Medical Stocks Lagging atai Life Sciences (ATAI) This Year? (Zacks)
Jun-24-25 03:51PM	Maxim Group Maintains a Buy on Atai Life Sciences (ATAI) With a $6 Price Target (Insider Monkey)
Jun-23-25 09:51AM	Compasss Psychedelic Drug to Treat Depression Meets Goal in Trial (Bloomberg) -18.55%
Jun-19-25 10:10AM	Trump Trade: President said to weigh possible U.S. strike against Iran (TipRanks)
09:26AM	Psychedelic advocates hopeful Trump administration will support space, STAT says (TipRanks)
12:01AM	This Illegal Psychedelic Is Hailed as a Revolutionary Breakthrough (WSJ)
Jun-09-25 12:00PM	Are You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great Choice (Zacks) -5.39%
09:40AM	Is atai Life Sciences (ATAI) Stock Outpacing Its Medical Peers This Year? (Zacks)
Jun-02-25 06:00AM	atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies (GlobeNewswire) +7.79%
May-29-25 08:30AM	atai Life Sciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
May-23-25 12:00PM	atai Life Sciences N.V. (ATAI) Is Up 18.71% in One Week: What You Should Know (Zacks)
May-22-25 09:55AM	atai Life Sciences N.V. (ATAI) Just Flashed Golden Cross Signal: Do You Buy? (Zacks) +5.76%
09:40AM	Is atai Life Sciences (ATAI) Outperforming Other Medical Stocks This Year? (Zacks)
May-21-25 12:10PM	Phase 2a data for BPL-003 encouraging for Atai Life Sciences, says Jefferies (TipRanks) -6.83%
11:55AM	Home Depot backs outlook as U.S. sales ticked up: Morning Buzz (TipRanks)
May-20-25 07:00AM	atai Life Sciences Announces Positive Topline Data from Part 2 of Beckley Psytech's Phase 2a Study of BPL-003 in Combination with SSRIs for Treatment-Resistant Depression (GlobeNewswire) +11.41%
May-14-25 07:00AM	atai Life Sciences Reports First Quarter 2025 Financial Results and Recent Corporate Updates (GlobeNewswire)
May-13-25 07:01AM	atai Life Sciences Announces First Patient Dosed in Phase 2 Study of EMP-01 for the Treatment of Social Anxiety Disorder (GlobeNewswire)
Apr-21-25 08:46AM	Atai Life Sciences: Pipeline And Regulatory Uncertainties Warrant Hold Rating (Seeking Alpha)
Apr-11-25 11:05AM	Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial (TipRanks) +6.61%
Apr-02-25 03:35PM	Is Atai Life Sciences (ATAI) the Best German Stock to Buy According to Hedge Funds? (Insider Monkey) +19.35%
Mar-22-25 10:30AM	Psychedelic: Exclusive talk with biotech company Clearmind Medicine (TipRanks)
Mar-21-25 11:50AM	Psychedelic: atai Life Sciences, NRx report quarterly results (TipRanks) +5.84%
Mar-17-25 08:00AM	atai Life Sciences Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights (GlobeNewswire)
Mar-14-25 11:40AM	Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial (TipRanks) +6.47%
Mar-11-25 07:00AM	atai Life Sciences Announces First Patient Dosed in Elumina, the Phase 2 Clinical Trial of VLS-01 for Treatment-Resistant Depression (GlobeNewswire)
Mar-05-25 07:00AM	atai Life Sciences Announces Completion of Enrollment in Phase 2b Clinical Trial Evaluating BPL-003 for Treatment-Resistant Depression (GlobeNewswire)
Mar-01-25 11:08AM	Atai Life Sciences N.V. (ATAI): Among the Best Psychedelic Stocks to Buy in 2025 (Insider Monkey)
Feb-28-25 11:30AM	Psychedelic: GH Research, Compass Pathways report earnings results (TipRanks)
Feb-24-25 04:10PM	atai Life Sciences to Participate in the TD Cowen 45th Annual Health Care Conference (GlobeNewswire) -8.54% -5.49%
Feb-20-25 07:00AM	atai Life Sciences Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Common Shares (GlobeNewswire)
Feb-12-25 10:47PM	atai Life Sciences Announces Pricing of Public Offering of Common Shares (GlobeNewswire) +14.35% -10.98%
04:01PM	atai Life Sciences Announces Proposed Public Offering of Common Shares (GlobeNewswire)
Feb-03-25 08:24AM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive) +19.35%
Jan-28-25 07:00AM	atai Life Sciences Announces Positive Topline Results from Beckley Psytech's BPL-003 (intranasal 5-MeO-DMT benzoate) Phase 2a Open-Label Study for Alcohol Use Disorder (GlobeNewswire)
Jan-12-25 07:58PM	Weekly Roundup on the Cannabis Sector & Psychedelic Sector (Market Exclusive)
Jan-10-25 07:00AM	atai Life Sciences Announces Key Leadership Appointments as it Advances its Pipeline of Novel Psychedelic Therapeutics for Mental Health (GlobeNewswire) -7.41%
Nov-13-24 08:00AM	atai Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates (GlobeNewswire) -7.53%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire) +12.06%
Oct-15-24 08:00AM	atai Life Sciences to Participate in the 2024 Maxim Healthcare Virtual Summit (GlobeNewswire)

Atai Beckley, Inc. is a clinical-stage biopharmaceutical company focused on developing effective, rapid-acting, and convenient mental health treatments. The company is headquartered in New York, NY.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Apeiron Investment Group Ltd.	10% Owner	Aug 14 '25	Buy	2.19	8,675,799	19,000,000	51,045,214	Aug 18 06:00 PM
SAHIL KIRPEKAR	Officer	Jul 02 '25	Proposed Sale	2.81	83,332	233,830		Jul 02 04:13 PM
SAHIL KIRPEKAR	Officer	Jul 01 '25	Proposed Sale	2.77	106,093	294,381		Jul 01 04:16 PM
SAHIL KIRPEKAR	Officer	Jun 04 '25	Proposed Sale	2.48	80,000	198,408		Jun 04 04:22 PM
Kirpekar Sahil	Chief Business Officer	Mar 21 '25	Sale	1.35	48,563	65,560	115,636	Mar 24 09:00 PM
Craig Kevin James	Chief Medical Officer	Mar 21 '25	Sale	1.35	11,563	15,610	8,437	Mar 24 09:00 PM
Rao Srinivas	See Remarks	Mar 21 '25	Sale	1.35	75,418	101,814	212,942	Mar 24 09:00 PM
Johnson Anne Nagengast	Chief Financial Officer	Mar 21 '25	Sale	1.35	33,545	45,286	140,045	Mar 24 09:00 PM
Short Glenn Frank	Chief Scientific Officer	Mar 21 '25	Sale	1.35	13,161	17,767	42,333	Mar 24 09:00 PM
FLORIAN BRAND	Officer	Mar 24 '25	Proposed Sale	1.54	100,000	154,090		Mar 24 05:10 PM
Apeiron Investment Group Ltd.	10% Owner	Mar 24 '25	Buy	1.40	1,800,000	2,520,000	42,369,415	Mar 24 05:00 PM
Brand Florian	Former Officer	Mar 19 '25	Proposed Sale	1.39	184,451	256,387		Mar 21 06:49 PM
Craig Kevin James	Officer	Mar 21 '25	Proposed Sale	1.39	11,563	16,073		Mar 21 06:46 PM
Short Glenn Frank	Officer	Mar 21 '25	Proposed Sale	1.39	13,161	18,294		Mar 21 06:42 PM
Johnson Anne Nagengast	Officer	Mar 21 '25	Proposed Sale	1.39	33,545	46,628		Mar 21 06:39 PM
Rao Srinivas	Officer	Mar 21 '25	Proposed Sale	1.39	75,418	104,831		Mar 21 06:35 PM
Kirpekar Sahil	Officer	Mar 21 '25	Proposed Sale	1.39	48,563	67,503		Mar 21 06:32 PM
FLORIAN OLAF BRAND	Officer	Mar 20 '25	Proposed Sale	1.38	300,000	412,560		Mar 20 04:39 PM
Apeiron Investment Group Ltd.	10% Owner	Feb 14 '25	Buy	2.10	10,835,718	22,755,008	40,555,215	Feb 19 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ATAI

AtaiBeckley Inc

Upgrade your FINVIZ experience